Skip to main content
TipRanks
Go Ultimate75% OFF

Laboratorios Farmaceuticos Rovi (ROVI) Stock Statistics & Valuation Metrics

46 Followers

Total Valuation

Laboratorios Farmaceuticos Rovi has a market cap or net worth of EUR 3.52B. The enterprise value is EUR 3.06B.

Market Cap
EUR 3.52B
Enterprise Value
EUR 3.06B

Share Statistics

Laboratorios Farmaceuticos Rovi has 51,235,764 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
51,235,764
Owned by Insiders
―
Owned by Institutions
5.29%

Financial Efficiency

Laboratorios Farmaceuticos Rovi’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 16.52%.

Return on Equity (ROE)
0.21
Return on Assets (ROA)
0.15
Return on Invested Capital (ROIC)
16.52%
Return on Capital Employed (ROCE)
0.22
Revenue Per Employee
333.10K
Profits Per Employee
62.92K
Employee Count
2,232
Asset Turnover
0.78
Inventory Turnover
1.01

Valuation Ratios

The current PE Ratio of Laboratorios Farmaceuticos Rovi is 17.04. Laboratorios Farmaceuticos Rovi’s PEG ratio is 2.04.

PE Ratio
17.04
PS Ratio
4.23
PB Ratio
4.49
Price to FCF
29.49
Price to Operating Cash Flow
17.87
PEG Ratio
2.04

Income Statement

In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of 743.48M and earned 140.44M in profits. Earnings per share was 2.75.

Revenue
743.48M
Gross Profit
451.65M
Operating Income
173.14M
Pretax Income
183.26M
Net Income
140.44M
EBITDA
203.52M
Earnings Per Share (EPS)
2.75

Cash Flow

In the last 12 months, operating cash flow was 196.09M and capital expenditures -77.29M, giving a free cash flow of 118.80M billion.

Operating Cash Flow
196.09M
Free Cash Flow
118.80M
Free Cash Flow per Share
2.32

Dividends & Yields

Laboratorios Farmaceuticos Rovi pays an annual dividend of EUR 0.96, resulting in a dividend yield of 1.38%

Dividend Per Share
EUR 0.96
Dividend Yield
1.38%
Payout Ratio
26.51%
Free Cash Flow Yield
3.39%
Earnings Yield
5.87%

Stock Price Statistics

Beta
0.59
52-Week Price Change
17.50%
50-Day Moving Average
60.60
200-Day Moving Average
65.42
Relative Strength Index (RSI)
73.19
Average Volume (3m)
106.02K

Important Dates

Laboratorios Farmaceuticos Rovi upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Feb 24, 2027
Ex-Dividend Date
Jul 13, 2026

Financial Position

Laboratorios Farmaceuticos Rovi as a current ratio of 3.14, with Debt / Equity ratio of 18.32%

Current Ratio
3.14
Quick Ratio
1.55
Debt to Market Cap
0.03
Net Debt to EBITDA
0.12
Interest Coverage Ratio
60.84

Taxes

In the past 12 months, Laboratorios Farmaceuticos Rovi has paid 42.90M in taxes.

Income Tax
42.90M
Effective Tax Rate
0.23

Enterprise Valuation

Laboratorios Farmaceuticos Rovi EV to EBITDA ratio is 12.76, with an EV/FCF ratio of 29.74.

EV to Sales
4.26
EV to EBITDA
12.76
EV to Free Cash Flow
29.74
EV to Operating Cash Flow
18.02

Balance Sheet

Laboratorios Farmaceuticos Rovi has EUR 70.92M in cash and marketable securities with EUR 100.95M in debt, giving a net cash position of -EUR 30.03M billion.

Cash & Marketable Securities
EUR 70.92M
Total Debt
EUR 100.95M
Net Cash
-EUR 30.03M
Net Cash Per Share
-EUR 0.59
Tangible Book Value Per Share
EUR 14.92

Margins

Gross margin is 64.38%, with operating margin of 21.51%, and net profit margin of 24.81%.

Gross Margin
64.38%
Operating Margin
21.51%
Pretax Margin
30.75%
Net Profit Margin
24.81%
EBITDA Margin
33.41%
EBIT Margin
29.06%

Analyst Forecast

The average price target for Laboratorios Farmaceuticos Rovi is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
14.41%
EPS Growth Forecast
69.69%

Scores

Smart Score
4
AI Score
76